Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant hypertension and heart failure, announces that it will present preclinical results of firibastat in post-myocardial ischemia heart failure at the Gordon Research Conference dedicated to the renin angiotensin aldosterone system, which will be held from 8 to 14 February in Barga (Lucca, Italy).

Dr. Solene Boitard-Joanne, Department of Pharmacology at Quantum Genomics, will present preclinical results of firibastat in mice after myocardial infarction, obtained in collaboration with the INSERM team led by Dr. Catherine Llorens-Cortes at the College de France. These results, published recently in the Journal of Molecular and Cellular Cardiology, demonstrate the efficacy of firibastat in improving cardiac function and preventing the onset of heart failure after a myocardial infarction (Boitard et al, 2019).

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach targeting the brain directly, it draws on more than twenty years of research work from Paris-Descartes University and the INSERM / CNRS laboratory led by Dr. Catherine Llorens-Cortes at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant hypertension (around 30% of patients are poorly controlled or have failed treatment), and

Contact:

Marc Karako

Tel: 01 85 34 77 75

Email: marc.karako@quantum-genomics.com

(C) 2020 Electronic News Publishing, source ENP Newswire